346 related articles for article (PubMed ID: 22669041)
41. Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells.
Chen MC; Lee CF; Huang WH; Chou TC
Biochem Pharmacol; 2013 May; 85(9):1278-87. PubMed ID: 23416116
[TBL] [Abstract][Full Text] [Related]
42. (-)-Gossypol suppresses the growth of human prostate cancer xenografts via modulating VEGF signaling-mediated angiogenesis.
Pang X; Wu Y; Wu Y; Lu B; Chen J; Wang J; Yi Z; Qu W; Liu M
Mol Cancer Ther; 2011 May; 10(5):795-805. PubMed ID: 21372225
[TBL] [Abstract][Full Text] [Related]
43. Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis.
Bi YL; Mi PY; Zhao SJ; Pan HM; Li HJ; Liu F; Shao LR; Zhang HF; Zhang P; Jiang SL
Int J Mol Med; 2017 May; 39(5):1255-1261. PubMed ID: 28358414
[TBL] [Abstract][Full Text] [Related]
44. DDA suppresses angiogenesis and tumor growth of colorectal cancer in vivo through decreasing VEGFR2 signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Oncotarget; 2016 Sep; 7(39):63124-63137. PubMed ID: 27517319
[TBL] [Abstract][Full Text] [Related]
45. Clinically relevant concentrations of lidocaine inhibit tumor angiogenesis through suppressing VEGF/VEGFR2 signaling.
Gao J; Hu H; Wang X
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1007-1015. PubMed ID: 30887179
[TBL] [Abstract][Full Text] [Related]
46. Indirubin derivative E804 inhibits angiogenesis.
Shin EK; Kim JK
BMC Cancer; 2012 May; 12():164. PubMed ID: 22554053
[TBL] [Abstract][Full Text] [Related]
47. Rutacecarpine Inhibits Angiogenesis by Targeting the VEGFR2 and VEGFR2-Mediated Akt/mTOR/p70s6k Signaling Pathway.
Ji L; Wu M; Li Z
Molecules; 2018 Aug; 23(8):. PubMed ID: 30111763
[TBL] [Abstract][Full Text] [Related]
48. The anti-angiogenic action of 2-deoxyglucose involves attenuation of VEGFR2 signaling and MMP-2 expression in HUVECs.
Chuang IC; Yang CM; Song TY; Yang NC; Hu ML
Life Sci; 2015 Oct; 139():52-61. PubMed ID: 26285173
[TBL] [Abstract][Full Text] [Related]
49. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
[TBL] [Abstract][Full Text] [Related]
50. Oroxyloside inhibits angiogenesis through suppressing internalization of VEGFR2/Flk-1 in endothelial cells.
Zhao K; Li X; Lin B; Yang D; Zhou Y; Li Z; Guo Q; Lu N
J Cell Physiol; 2018 Apr; 233(4):3454-3464. PubMed ID: 28926106
[TBL] [Abstract][Full Text] [Related]
51. Norcantharidin: a potential antiangiogenic agent for gallbladder cancers in vitro and in vivo.
Zhang JT; Fan YZ; Chen CQ; Zhao ZM; Sun W
Int J Oncol; 2012 May; 40(5):1501-14. PubMed ID: 22200632
[TBL] [Abstract][Full Text] [Related]
52. Harmine suppresses bladder tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis.
Hai-Rong C; Xiang H; Xiao-Rong Z
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30910851
[TBL] [Abstract][Full Text] [Related]
53. Norcantharidin inhibits tumor angiogenesis via blocking VEGFR2/MEK/ERK signaling pathways.
Zhang L; Ji Q; Liu X; Chen X; Chen Z; Qiu Y; Sun J; Cai J; Zhu H; Li Q
Cancer Sci; 2013 May; 104(5):604-10. PubMed ID: 23363445
[TBL] [Abstract][Full Text] [Related]
54. Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signal-regulated kinase signaling pathways.
Pang X; Yi T; Yi Z; Cho SG; Qu W; Pinkaew D; Fujise K; Liu M
Cancer Res; 2009 Jan; 69(2):518-25. PubMed ID: 19147565
[TBL] [Abstract][Full Text] [Related]
55. PBA2 exhibits potent anti-tumor activity via suppression of VEGFR2 mediated-cell proliferation and angiogenesis.
Fang X; Xie H; Luo M; Chen Z; Wang F; Li Q; Wang X; Ding J; Fu L
Biochem Pharmacol; 2018 Apr; 150():131-140. PubMed ID: 29408327
[TBL] [Abstract][Full Text] [Related]
56. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
[TBL] [Abstract][Full Text] [Related]
57. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
[TBL] [Abstract][Full Text] [Related]
58. AGS-30, an andrographolide derivative, suppresses tumor angiogenesis and growth in vitro and in vivo.
Li J; Li F; Tang F; Zhang J; Li R; Sheng D; Lee SM; Zhou GC; Leung GP
Biochem Pharmacol; 2020 Jan; 171():113694. PubMed ID: 31706845
[TBL] [Abstract][Full Text] [Related]
59. FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.
Gao W; Jin K; Lan H; Han N; Cao F; Teng L
Hepatogastroenterology; 2012; 59(120):2543-7. PubMed ID: 22534543
[TBL] [Abstract][Full Text] [Related]
60. Rhamnazin, a novel inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy.
Yu Y; Cai W; Pei CG; Shao Y
Biochem Biophys Res Commun; 2015 Mar; 458(4):913-9. PubMed ID: 25704088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]